Related Experiment Video
Updated: Apr 18, 2026

Site-Directed Mutagenesis for In Vitro and In Vivo Experiments Exemplified with RNA Interactions in Escherichia Coli
Published on: February 5, 2019
Semi-Rational Engineering of rhArg1 via Non-Conserved Residue Mutagenesis for Enhanced Efficiency and Stability
Shuai Fan1, Cuiyue Feng2, Wenbang Wang1
1NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Abstract:
Arginase 1 deficiency is a rare inherited metabolic disorder characterized by progressive neurological dysfunction. Although recombinant human arginase 1 (rhArg1) has been investigated as a therapeutic enzyme, its clinical potential is limited by insufficient catalytic activity and stability. In this study, we applied an evolutionary conservation-guided design strategy to enhance rhArg1 activity by targeting low-conservation residues within the catalytic pocket. Seven candidate sites were identified, and 29 variants were generated by site-directed and combinatorial mutagenesis. Under 2 mM Mn2+ conditions, several mutants (N139K, Q143K, and Q143S) exhibited 1.4-1.6 fold increases in kcat relative to the wild type. Notably, under Mn2+-free conditions, the double mutant T136D/Q143V showed a 1.5-fold increase in kcat and a 73% improvement in kcat/KM. Molecular dynamics simulations revealed that these mutations enhance catalytic performance by promoting near-attack conformations. This work demonstrates an effective rational strategy for improving rhArg1 catalytic efficiency and stability, supporting its therapeutic development.
Related Concept Videos
Homologous Recombination
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...

